Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

NEUROGENETICS is a distinguished journal published by SPRINGER, focusing on the intersection of genetics and neuroscience. With its ISSN 1364-6745 and E-ISSN 1364-6753, this journal has been a vital resource in the fields of cellular and molecular neuroscience and genetics since its establishment in 1997. As of 2023, it is ranked Q3 in Cellular and Molecular Neuroscience and Q2 in both Genetics and Clinical Genetics, reflecting its growing influence and importance in these areas. Although not an open-access journal, it provides significant insights and research findings that contribute to advancing our understanding of genetic influences on neural function and disease. Based in Germany with an address at ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES, NEUROGENETICS serves as a crucial platform for researchers, professionals, and students alike to explore innovative studies that are essential for the future of neuroscience and genetics. With its continuous commitment to high-quality research, the journal aims to foster collaboration and knowledge dissemination among the scientific community.

Neurology and Clinical Neuroscience, published by WILEY, is a pivotal peer-reviewed journal dedicated to advancing knowledge in the fields of neurology and clinical neuroscience. With an ISSN of 2049-4173, it encompasses a diverse range of topics related to neurological disorders, offering a platform for groundbreaking research and clinical practices. Although the journal does not currently operate under an open access model, it aims to foster an inclusive academic environment by providing high-quality content that is accessible to both specialists and general practitioners in the medical community. Despite its relatively recent establishment from 2013 to 2024, the journal has gained recognition with Scopus rankings highlighting its role in clinical neurology and neuroscience spheres. It serves as an essential resource for researchers, professionals, and students seeking to expand their understanding and engage in current discussions surrounding neurological health and diseases.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

Journal of Pediatric Neurology, published by GEORG THIEME VERLAG KG, stands as a dedicated resource in the field of pediatric neurology, navigating the complex interplay of neurological and developmental disorders affecting children. With its ISSN 1304-2580 and E-ISSN 1875-9041, this journal has been a pivotal platform for advancing research since its inception in 2003, and continues to present critical findings and discussions up to 2024. Although currently categorized in the Q4 quartile for both Neurology (Clinical) and Pediatrics, Perinatology and Child Health within Scopus rankings, the journal's commitment to fostering scholarly dialogue is essential for researchers, clinicians, and students dealing with pediatric patients. Its structured coverage of various neurological disorders, treatment strategies, and innovative therapies contributes to the broader understanding of pediatric neurology, despite the challenges noted in its ranking percentile. By encouraging submissions from diverse disciplines, the journal aims to enhance clinical practice and bridge gaps in knowledge, ensuring a multidisciplinary approach to child health and development.

Journal of Neuromuscular Diseases, published by IOS PRESS, is a leading platform dedicated to advancing the field of neurology and neuromuscular research. With a focus on delivering high-quality, peer-reviewed content, this journal aims to foster knowledge sharing and collaboration among researchers, clinicians, and healthcare professionals dealing with neuromuscular disorders. The journal boasts a commendable impact factor within its respective categories, achieving Q2 rankings in both Neurology and Clinical Neurology as of 2023. Spanning from its inception in 2014 to the anticipated convergence in 2024, it is recognized for its contributions to critical discussions in the field, evidenced by its rankings of #145 out of 400 in clinical neurology and #75 out of 192 in neuroscience. As an open access journal, it facilitates wider accessibility of research findings, catering to an audience eager for innovative approaches and developments. Set against the backdrop of the vibrant academic scene in the Netherlands, the Journal of Neuromuscular Diseases serves as an essential resource for driving forward the boundaries of knowledge in neuromuscular-related conditions.

Open Access Rheumatology-Research and Reviews, published by DOVE MEDICAL PRESS LTD, is a distinguished journal that has been a vital part of the rheumatology field since its inception in 2009. With an ISSN of 1179-156X, this journal is dedicated to disseminating groundbreaking research and comprehensive reviews in the discipline of rheumatology, making it an essential resource for researchers, clinicians, and students alike. It boasts an impressive Q3 ranking in the Rheumatology category for 2023, reflecting its relevance and quality within a highly competitive landscape, where it ranks in the 51st percentile among its peers as indicated by the Scopus Ranks. As an open-access platform, it ensures that critical findings and insights are easily accessible to a global audience, promoting collaboration and knowledge sharing. The journal's scope includes a wide range of topics within rheumatology, aimed at advancing understanding and treatment of musculoskeletal disorders and autoimmune diseases. Its headquarters is located in New Zealand, positioning it as a key player in the international research community.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

ACTA NEUROLOGICA SCANDINAVICA is a prestigious journal published by Wiley that has significantly contributed to the field of neurology and neuroscience since its inception in 1961. With a broad scope encompassing clinical and experimental research, this journal is esteemed for its rigorous peer-review process and high-quality publications. Located in the United Kingdom, it is recognized in the 2023 category quartiles as Q1 in Medicine (miscellaneous) and Q2 in both Neurology and Clinical Neurology, indicating its strong influence and relevance within the medical community. With an H-index demonstrating consistent citation impact, ACTA NEUROLOGICA SCANDINAVICA holds a Scopus rank of #86 out of 400 in Clinical Neurology, reflecting its contribution to advancing current knowledge and practice. Researchers, professionals, and students alike will find in this journal a valuable resource for the latest findings, discussions, and developments in understanding neurological disorders and treatments, furthering educational and clinical endeavors alike.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.